Mainstay Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.49M Buy
1,618
+55
+4% +$55.8K 0.11% 55
2025
Q4
$1.68M Buy
1,563
+31
+2% +$29.6K 0.13% 49
2025
Q3
$1.17M Sell
1,532
-1,416
-48% -$1.05M 0.12% 63
2025
Q2
$2.3M Buy
2,948
+1,505
+104% +$1.17M 0.11% 63
2025
Q1
$1.19M Buy
+1,443
New +$1.2M 0.16% 53
2024
Q4
Sell
-229
Closed -$203K 113
2024
Q3
$203K Buy
+229
New +$206K 0.03% 107
2022
Q3
Sell
-1,066
Closed -$346K 107
2022
Q2
$346K Buy
1,066
+32
+3% +$9.61K 0.08% 80
2022
Q1
$296K Sell
1,034
-115
-10% -$29.6K 0.05% 95
2021
Q4
$317K Buy
+1,149
New +$291K 0.1% 95
2021
Q3
Sell
-1,149
Closed -$264K 118
2021
Q2
$264K Hold
1,149
0.06% 105
2021
Q1
$214K Buy
+1,149
New +$225K 0.07% 122
2018
Q4
Sell
-1,218
Closed -$131K 256
2018
Q3
$131K Buy
1,218
+603
+98% +$60.3K 0.08% 124
2018
Q2
$52K Buy
615
+467
+316% +$38.4K 0.04% 173
2018
Q1
$11K Buy
148
+104
+236% +$8.37K 0.01% 235
2017
Q4
$4K Buy
+44
New +$3.74K ﹤0.01% 302

Other funds holding LLY

Mainstay Capital Management's LLY Position: Q1 2026 in Review

Mainstay Capital Management increased its Eli Lilly (LLY) stake by 3.5% in Q1 2026, buying an estimated $55.8K and bringing the position to 1,618 shares worth $1.49M. The position accounts for 0.11% of the portfolio, ranked #55.

Mainstay Capital Management first reported a position in LLY in Q4 2017 and has held it in 15 quarters since. The position peaked at $2.3M in Q2 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Mainstay Capital Management held 1,618 shares of Eli Lilly worth $1.49M as of Q1 2026.
  • Mainstay Capital Management bought 55 Eli Lilly shares in Q1 2026, an estimated $55.8K.
  • Eli Lilly made up 0.11% of Mainstay Capital Management's portfolio in Q1 2026, its #55 holding.
  • Mainstay Capital Management first reported a position in Eli Lilly in Q4 2017 and has held it in 15 quarters since.
  • Mainstay Capital Management's Eli Lilly position peaked at $2.3M in Q2 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Mainstay Capital Management's 13F filing for Q1 2026, filed 12 May 2026.